COMBINATION THERAPY FOR TREATING LUNG CANCER

The present invention relates to methods fortreating small cell lung cancer (SCLC), in particular small cell lung cancer (SCLC) in a subject in need thereof wherein a therapeutically efficient amount of a radiopharmaceutical compound comprising a SSTR binding moiety, in particular [177Lu]Lu-DOTATE i...

Full description

Saved in:
Bibliographic Details
Main Authors FOLITAR, Ilya, AIMONE, Paola Daniela, MARIANI, Maurizio F, CHICCO, Daniela
Format Patent
LanguageEnglish
French
Published 19.05.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to methods fortreating small cell lung cancer (SCLC), in particular small cell lung cancer (SCLC) in a subject in need thereof wherein a therapeutically efficient amount of a radiopharmaceutical compound comprising a SSTR binding moiety, in particular [177Lu]Lu-DOTATE is administered to said subject in combination with one or more chemotherapeutic agents, such as carboplatin and etoposide, and, optionally an immune- oncology (I/O) agent, such as tislelizumab. La présente invention concerne des méthodes de traitement du cancer du poumon à petites cellules, en particulier du cancer du poumon à petites cellules chez un sujet qui le nécessite, une quantité thérapeutiquement efficace d'un composé radiopharmaceutique comprenant une fraction de liaison SSTR, en particulier [177Lu]Lu-DOTATE, étant administrée audit sujet en association avec un ou plusieurs agents chimiothérapeutiques, tels que le carboplatine et l'étoposide, et, éventuellement, un agent d'immuno-oncologie (I/O), tel que le tislelizumab.
Bibliography:Application Number: WO2022IB60840